Skip to content

Reference

Evidence

CompoundsSubstances with curated findings
OutcomesMeasured endpoints
ProteinsTransporters and enzymes
InteractionsPairs that share biology
PapersEvery paper a finding cites

Reference layer

PathwaysReactions grouped under one name
ProcessesWhat proteins are annotated as doing
AnatomyTissues, by what is expressed there
Cell typesCells, by what is expressed there
OrganismsSpecies a compound is prepared from
MaterialsSubstances that are not one molecule
AssessmentsRegulatory determinations, transcribed

Atlas Graph Access

Search the graph

Atlas Graph Access Compounds Outcomes Proteins Interactions Papers Pathways Processes Anatomy Cell types Organisms Materials Assessments

Loading the page.

Catalyst

The evidence graph for human biochemistry. Every edge carries its source, its study design, and a grade computed from both.

The graph

Compounds
Outcomes
Proteins
Atlas
Interactions
Papers
Graph
Search

Reference layer

Pathways
Processes
Anatomy
Cell types
Organisms
Materials
Assessments

How it works

Mission
Method
How to read the evidence
Sources and licences

Build on it

Access
For agents
Query the graph
Bulk export

A reference for what the literature reports. Not medical advice.

© 2026 CatalystPrivacy TermsReference data under the licences listed on the attribution page.

Papers/PMID:36121807

Comparative efficacy and safety of caffeine citrate and aminophylline in treating apnea of prematurity: A systematic review and meta-analysis.

PloS one2022The record

1 finding drawn from this paper, on 1 compound across 1 endpoint.

caffeine

What it reported

How to read these marks

What moved

1 finding

caffeine — decreases adverse reaction incidence (unstandardised)
LikelyGrade B, Likely. Human evidence, limited replication or design limits.Finding
“The analysis found that compared with aminophylline, infants in the caffeine group had a lower chance of developing total adverse effects (OR 0.41, 95%CI: 0.17–0.97, P = 0.042).”
Quoted verbatim from Comparative efficacy and safety of caffeine citrate and aminophylline in treating apnea of prematurity: A systematic review and meta-analysis..
Study

meta-analysis
Population

Preterm infants (<37 weeks gestation) with apnea of prematurity; caffeine citrate against an ACTIVE COMPARATOR (aminophylline), not placebo; safety outcome pooled from 4 of the 10 included studies.
Effect 0.41 odds ratio, 95% CI 0.17 to 0.97
Comparative efficacy and safety of caffeine citrate and aminophylline in treating apnea of prematurity: A systematic review and meta-analysis.2022PMID:36121807